Hims & Hers Health, Inc. (OAC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1250070,
    "name": "Hims & Hers Health, Inc.",
    "stock_name": "Hims & Hers Health, Inc.",
    "full_name": "Hims & Hers Health, Inc.",
    "name_url": "stocks-analysis/hims-hers-health-inc",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "40.02",
    "chg": 2.95,
    "chgp": "7.96%",
    "dir": 1,
    "prev_price": "37.07",
    "mcapval": "11,219.61",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 3365,
    "indexname": "S&P 500",
    "isin": "US4330001060",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "49.51 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/hims-hers-health-inc-1250070-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Hims & Hers Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hims-hers-health-inc-overvalued-or-undervalued-3651102",
        "imagepath": "",
        "date": "2025-10-28 11:13:03",
        "description": "As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a PEG ratio of 0.01, indicating potential growth relative to its price.\n\nIn comparison to peers, Hims & Hers has a P/E ratio that is higher than Addus HomeCare Corp. at 22.05 and significantly higher than Guardant Health, Inc., which has a negative P/E of -17.69. Despite the high valuation ratios, the company's strong ROCE of 50.18% and ROE of 30.96% suggest robust profitability. Over the past year, Hims & Hers has outperformed the S&P 500 with a return of 126.67% compared to the index's 16.90%, reinforcing its favorable valuation outlook...."
      },
      {
        "title": "Hims & Hers Health, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/hims-hers-health-changes-valuation-grade-from-expensive-to-fair-amid-stock-surge-3649140",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/HimsHersHealthI_valuationdot_3649140.png",
        "date": "2025-10-27 16:11:32",
        "description": "Hims & Hers Health, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 74 and a price-to-book value of 22.96. The company boasts a strong return on capital employed at 50.18% and a year-to-date return of 101.74%, amid significant stock volatility."
      },
      {
        "title": "Is Hims & Hers Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hims-hers-health-inc-overvalued-or-undervalued-3647608",
        "imagepath": "",
        "date": "2025-10-27 11:13:11",
        "description": "As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 74, a Price to Book Value of 22.96, and an EV to EBITDA of 89.10. In comparison, Guardant Health, Inc. has a P/E of -17.69 and an EV to EBITDA of -19.11, while Addus HomeCare Corp. shows a fair valuation with a P/E of 22.05 and an EV to EBITDA of 15.27.\n\nDespite recent underperformance against the S&P 500 over the past week and month, Hims & Hers has demonstrated impressive year-to-date and one-year returns of 101.74% and 126.67%, respectively, significantly outpacing the index. This strong performance, combined with its fair valuation, suggests that the stock may have room for growth moving forward...."
      },
      {
        "title": "Is Hims & Hers Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hims-hers-health-inc-overvalued-or-undervalued-3646149",
        "imagepath": "",
        "date": "2025-10-26 11:09:43",
        "description": "As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a PEG ratio of 0.01, indicating that while the company has high earnings expectations, it is not currently generating proportional growth.\n\nIn comparison to peers, Hims & Hers Health, Inc. has a higher P/E ratio than Addus HomeCare Corp., which stands at 22.05, and is significantly higher than Guardant Health, Inc., which has a negative P/E of -17.69. The company's strong ROCE of 50.18% and ROE of 30.96% suggest efficient capital utilization, although the elevated valuation ratios may still warrant caution. Notably, Hims & Hers has outperformed the S&P 500 significantly over the past three years with a return of 1069.78% compared to the index's 78.85%, reinforcing a p..."
      },
      {
        "title": "Is Hims & Hers Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hims-hers-health-inc-overvalued-or-undervalued-3637952",
        "imagepath": "",
        "date": "2025-10-21 12:12:14",
        "description": "As of 17 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued, particularly given its high P/E ratio of 74, a price-to-book value of 22.96, and an EV to EBITDA ratio of 89.10, which are significantly above industry norms. In comparison, Guardant Health, Inc. has a P/E ratio of -17.69, while Addus HomeCare Corp. shows a fair valuation with a P/E of 22.05, highlighting the relative overvaluation of Hims & Hers.\n\nDespite strong recent performance, with a year-to-date return of 105.87% compared to the S&P 500's 13.30%, the elevated valuation ratios suggest that the stock may not sustain its current price levels. The company's high PEG ratio of 0.01 further complicates the valuation picture, indicating that future growth expectations may already be priced in. Overal..."
      },
      {
        "title": "Is Hims & Hers Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hims-hers-health-inc-overvalued-or-undervalued-3634821",
        "imagepath": "",
        "date": "2025-10-20 12:29:30",
        "description": "As of 17 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 74, a Price to Book Value of 22.96, and an EV to EBITDA of 89.10. In comparison, Guardant Health, Inc. has a P/E of -17.69, while Addus HomeCare Corp. shows a more reasonable P/E of 22.05, highlighting the relative expense of Hims & Hers.\n\nDespite a strong year-to-date return of 105.87% compared to the S&P 500's 13.30%, the high valuation ratios suggest that the stock may not sustain such performance in the long run. The company's PEG ratio of 0.01 further emphasizes its high valuation relative to growth expectations, reinforcing the conclusion that it is overvalued in the current market context...."
      },
      {
        "title": "Is Hims & Hers Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hims-hers-health-inc-overvalued-or-undervalued-3632359",
        "imagepath": "",
        "date": "2025-10-19 12:06:48",
        "description": "As of 17 October 2025, the valuation grade for Hims & Hers Health, Inc. moved from very expensive to expensive, indicating a shift towards a less favorable valuation. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a Price to Book Value of 22.96, which are significantly higher than many peers in the industry.\n\nIn comparison, Guardant Health, Inc. has a P/E of -17.69, while Addus HomeCare Corp. shows a more reasonable P/E of 22.05, highlighting the relative overvaluation of Hims & Hers. Despite strong returns of 130.89% over the past year compared to the S&P 500's 14.08%, the elevated valuation ratios suggest that the stock may not sustain its current price levels in the long term...."
      },
      {
        "title": "Hims & Hers Health, Inc. Experiences Evaluation Revision Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/hims-hers-health-inc-technical-trend-shifts-from-bullish-to-mildly-bullish-amid-stock-price-increase-3619991",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/HimsHersHealthI_technicaldot_3619991.png",
        "date": "2025-10-14 16:25:30",
        "description": "Hims & Hers Health, Inc. has recently revised its evaluation amid current market dynamics. The stock has shown impressive performance over the past year, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting both bullish and bearish trends, while the company continues to demonstrate strong growth potential."
      },
      {
        "title": "Is Hims & Hers Health, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-hims-hers-health-inc-technically-bullish-or-bearish-3617719",
        "imagepath": "",
        "date": "2025-10-14 11:39:18",
        "description": "As of 10 October 2025, the technical trend for Hims & Hers Health, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The Bollinger Bands show a bullish stance on the weekly and mildly bullish on the monthly. Daily moving averages are bullish, supporting a positive short-term outlook. However, the KST is mildly bearish weekly and bullish monthly, and the Dow Theory indicates no trend in both weekly and monthly views. \n\nIn terms of performance, the company has significantly outperformed the S&P 500 over the longer terms, with a year-to-date return of 126.34% compared to the S&P 500's 11.41%, and a one-year return of 192.83% against 13.36%. Overall, the current technical stance is mildly bullish, with strength derived from daily moving averages and the monthly MACD...."
      }
    ],
    "total": 21,
    "sid": "1250070",
    "stock_news_url": "https://www.marketsmojo.com/news/hims-hers-health-inc-1250070"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Hims & Hers Health, Inc. overvalued or undervalued?

2025-10-28 11:13:03

As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key valuation ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a PEG ratio of 0.01, indicating potential growth relative to its price. In comparison to peers, Hims & Hers has a P/E ratio that is higher than Addus HomeCare Corp. at 22.05 and significantly higher than Guardant Health, Inc., which has a negative P/E of -17.69. Despite the high valuation ratios, the company's strong ROCE of 50.18% and ROE of 30.96% suggest robust profitability. Over the past year, Hims & Hers has outperformed the S&P 500 with a return of 126.67% compared to the index's 16.90%, reinforcing its favorable valuation outlook....

Hims & Hers Health, Inc. Experiences Revision in Its Stock Evaluation Amid Market Dynamics

2025-10-27 16:11:32

Hims & Hers Health, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 74 and a price-to-book value of 22.96. The company boasts a strong return on capital employed at 50.18% and a year-to-date return of 101.74%, amid significant stock volatility.

Is Hims & Hers Health, Inc. overvalued or undervalued?

2025-10-27 11:13:11

As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 74, a Price to Book Value of 22.96, and an EV to EBITDA of 89.10. In comparison, Guardant Health, Inc. has a P/E of -17.69 and an EV to EBITDA of -19.11, while Addus HomeCare Corp. shows a fair valuation with a P/E of 22.05 and an EV to EBITDA of 15.27. Despite recent underperformance against the S&P 500 over the past week and month, Hims & Hers has demonstrated impressive year-to-date and one-year returns of 101.74% and 126.67%, respectively, significantly outpacing the index. This strong performance, combined with its fair valuation, suggests that the stock may have room for growth moving forward....

Is Hims & Hers Health, Inc. overvalued or undervalued?

2025-10-26 11:09:43

As of 24 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a PEG ratio of 0.01, indicating that while the company has high earnings expectations, it is not currently generating proportional growth. In comparison to peers, Hims & Hers Health, Inc. has a higher P/E ratio than Addus HomeCare Corp., which stands at 22.05, and is significantly higher than Guardant Health, Inc., which has a negative P/E of -17.69. The company's strong ROCE of 50.18% and ROE of 30.96% suggest efficient capital utilization, although the elevated valuation ratios may still warrant caution. Notably, Hims & Hers has outperformed the S&P 500 significantly over the past three years with a return of 1069.78% compared to the index's 78.85%, reinforcing a p...

Is Hims & Hers Health, Inc. overvalued or undervalued?

2025-10-21 12:12:14

As of 17 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued, particularly given its high P/E ratio of 74, a price-to-book value of 22.96, and an EV to EBITDA ratio of 89.10, which are significantly above industry norms. In comparison, Guardant Health, Inc. has a P/E ratio of -17.69, while Addus HomeCare Corp. shows a fair valuation with a P/E of 22.05, highlighting the relative overvaluation of Hims & Hers. Despite strong recent performance, with a year-to-date return of 105.87% compared to the S&P 500's 13.30%, the elevated valuation ratios suggest that the stock may not sustain its current price levels. The company's high PEG ratio of 0.01 further complicates the valuation picture, indicating that future growth expectations may already be priced in. Overal...

Is Hims & Hers Health, Inc. overvalued or undervalued?

2025-10-20 12:29:30

As of 17 October 2025, the valuation grade for Hims & Hers Health, Inc. has moved from very expensive to expensive, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 74, a Price to Book Value of 22.96, and an EV to EBITDA of 89.10. In comparison, Guardant Health, Inc. has a P/E of -17.69, while Addus HomeCare Corp. shows a more reasonable P/E of 22.05, highlighting the relative expense of Hims & Hers. Despite a strong year-to-date return of 105.87% compared to the S&P 500's 13.30%, the high valuation ratios suggest that the stock may not sustain such performance in the long run. The company's PEG ratio of 0.01 further emphasizes its high valuation relative to growth expectations, reinforcing the conclusion that it is overvalued in the current market context....

Is Hims & Hers Health, Inc. overvalued or undervalued?

2025-10-19 12:06:48

As of 17 October 2025, the valuation grade for Hims & Hers Health, Inc. moved from very expensive to expensive, indicating a shift towards a less favorable valuation. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a Price to Book Value of 22.96, which are significantly higher than many peers in the industry. In comparison, Guardant Health, Inc. has a P/E of -17.69, while Addus HomeCare Corp. shows a more reasonable P/E of 22.05, highlighting the relative overvaluation of Hims & Hers. Despite strong returns of 130.89% over the past year compared to the S&P 500's 14.08%, the elevated valuation ratios suggest that the stock may not sustain its current price levels in the long term....

Hims & Hers Health, Inc. Experiences Evaluation Revision Amid Strong Market Performance

2025-10-14 16:25:30

Hims & Hers Health, Inc. has recently revised its evaluation amid current market dynamics. The stock has shown impressive performance over the past year, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting both bullish and bearish trends, while the company continues to demonstrate strong growth potential.

Is Hims & Hers Health, Inc. technically bullish or bearish?

2025-10-14 11:39:18

As of 10 October 2025, the technical trend for Hims & Hers Health, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The Bollinger Bands show a bullish stance on the weekly and mildly bullish on the monthly. Daily moving averages are bullish, supporting a positive short-term outlook. However, the KST is mildly bearish weekly and bullish monthly, and the Dow Theory indicates no trend in both weekly and monthly views. In terms of performance, the company has significantly outperformed the S&P 500 over the longer terms, with a year-to-date return of 126.34% compared to the S&P 500's 11.41%, and a one-year return of 192.83% against 13.36%. Overall, the current technical stance is mildly bullish, with strength derived from daily moving averages and the monthly MACD....

View All News